FDA launches safety study of abortion pill mifepristone.
The FDA has begun a retrospective safety study of mifepristone involving hundreds of thousands of cases, with interim results potentially released in July. The study could inform future Trump administration decisions on restricting access to the medication.
3
Divergence score
4 outlets covered it, splitting into 4 framing camps across 3 bias groups.
4 camps
3 bias groups
The spectrum · how 4 outlets placed this story
LeftCenterRight
CBS News
Reuters
Wall Street Journal
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Coverage splits between political victory framing (WSJ, The Hill) emphasizing anti-abortion group wins and procedural neutrality (CBS, Reuters) reporting FDA safety review as routine process.
How each outlet covered it
Broad agreement on what happened
Outlets across the spectrum land in roughly the same place: the shared language is highlighted.
THE LEFT
“FDA launches safety study for abortion pill mifepristone, source says”CBS CBS News LEFT-CENTER
3LOW DIVERGENCE
THE RIGHT
“Exclusive | FDA Launches Study of Abortion Pill Safety as Opponents Push for Limits - WSJ”WSJ Wall Street Journal RIGHT-CENTER
DOWN THE MIDDLE
“FDA reviewing safety of abortion drug mifepristone” · Reuters, The Hill
+Hide the full sourcingSee how all 4 outlets put it
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed